<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00613652</url>
  </required_header>
  <id_info>
    <org_study_id>D2782C00008</org_study_id>
    <nct_id>NCT00613652</nct_id>
  </id_info>
  <brief_title>A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients</brief_title>
  <official_title>A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Weekly in Japanese Adult Patients With Advanced Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and tolerability of AZD4877 on a
      weekly schedule in Japanese patients with advanced solid malignancies
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the PK profile of AZD4877 on a weekly schedule in Japanese patients with advanced solid malignancies</measure>
    <time_frame>weekly</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cancer</condition>
  <condition>Tumors</condition>
  <condition>Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD4877</intervention_name>
    <description>10 mg IV (3 weeks treatment 1 week rest)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with solid tumour but which have no standard treatment or did not
             respond to previous treatments.

          -  Patients who usually have mild symptoms capable of walking and light and sedentary
             work.

          -  Patients who can stay in hospital at least during 4 weeks.

        Exclusion Criteria:

          -  Patients who have received treatment with anti-cancer agent within 4 weeks prior to
             first dose of study treatment; 6 weeks if the anti-cancer agent is mitomycin.

          -  Patients with abnormally low levels of neutrophil count, platelet count, or
             haemoglobin, indicators of bone marrow function.

          -  Patients who received therapeutic radiotherapy at central nervous system within 3
             months prior to first dose of study treatment; the other sites within 4 weeks; or
             local site within 2 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2008</study_first_submitted>
  <study_first_submitted_qc>January 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2008</study_first_posted>
  <last_update_submitted>July 20, 2009</last_update_submitted>
  <last_update_submitted_qc>July 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2009</last_update_posted>
  <keyword>solid tumors</keyword>
  <keyword>solid malignancies</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

